摘要
2025年3月,美国肝病学会发布了最新版针对儿童代谢相关脂肪性肝病(MASLD)的实践声明。与既往指南相比,该声明采纳了最新的MASLD命名和诊断标准,强调肝脂肪变性合并至少1项心血管代谢危险因素,重点阐述了儿童MASLD独特的流行病学特征、病理生理模式、疾病自然史。该声明基于循证医学证据,为儿童MASLD的筛查、诊断、治疗和监测提供了全面指导,强调生活方式干预是治疗的基石,目前尚无任何药物被批准用于儿童MASLD的治疗。本文对该实践声明中的要点进行摘译。
In March 2025,the American Association for the Study of Liver Diseases published its latest practice statement on metabolic dysfunction-associated steatotic liver disease(MASLD)in children.Compared with previous guidelines,this statement adopts the latest nomenclature and diagnostic criteria for MASLD,emphasizes hepatic steatosis in the presence of at least one cardiovascular metabolic risk factor,and elaborates on the unique epidemiological characteristics,pathophysiological patterns,and natural history of pediatric MASLD.Based on evidence-based medicine,the statement provides comprehensive guidance on the screening,diagnosis,treatment and monitoring of MASLD in children and emphasizes that lifestyle interventions form the cornerstone of treatment,and at present,there are still no drugs approved for the treatment of MASLD in children.This article gives an excerpt of the key recommendations in the practice statement.
作者
刘佳程
饶慧瑛
LIU Jiacheng;RAO Huiying(Peking University People’s Hospital,Peking University Hepatology Institute,Beijing 100044,China)
出处
《临床肝胆病杂志》
北大核心
2025年第11期2248-2251,共4页
Journal of Clinical Hepatology
关键词
代谢相关脂肪性肝病
儿童
美国
诊疗准则
Metabolic Dysfunction-Associated Steatotic Liver Disease
Child
United States
Practice Guideline
